Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

On October 1, 2019 Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, reported the acceptance of an abstract highlighting data from the AWARE-1 study to be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, Oncolytics Biotech, OCT 1, 2019, View Source [SID1234539971]). The 34th Annual SITC (Free SITC Whitepaper) Meeting will be held November 6-10, 2019 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, A window-of-opportunity Study of pelareorep in Early Breast Cancer (AWARE-1), was authored by AWARE-1 principal investigator, Aleix Prat, et al. Dr. Prat is Head of Medical Oncology at the Hospital Clínic of Barcelona, Associate Professor of the University of Barcelona and the Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Group at August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and member of Oncolytics’ Scientific Advisory Board.

Abstracts will be published on the SITC (Free SITC Whitepaper) 2019 website at 8:00 a.m. ET on Tuesday, November 5, 2019.

The poster will be presented on Friday, November 8 between 7:00 a.m. and 8:00 p.m. ET.

About Pelareorep

Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers and has been demonstrated to be able to escape neutralizing antibodies found in patients.